Book a Meeting

Non-Fucosylated Anti-Human Thrombin (ichorcumab) Therapeutic Antibody (CAT#: BioBet-851ZP) Datasheet

Target
Thrombin
Isotype
IgG4
Description
ADCC-Enhanced anti-Thrombin (ichorcumab) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Thromboembolism
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Thrombin antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
F2
Full Name
coagulation factor II (thrombin)
Background
Coagulation factor II is proteolytically cleaved to form thrombin in the first step of the coagulation cascade which ultimately results in the stemming of blood loss. F2 also plays a role in maintaining vascular integrity during development and postnatal life. Finally, peptides derived from the C-terminus of this protein have antimicrobial activity against E. coli and P. aeruginosa. Mutations in F2 leads to various forms of thrombosis and dysprothrombinemia.
Alternative Names
F2; coagulation factor II (thrombin); PT; THPH1; RPRGL2; prothrombin; serine protease; prothrombin B-chain; prepro-coagulation factor II
Gene ID
2147
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with F2 include Prothrombin Deficiency, Congenital and Thrombophilia Due To Thrombin Defect.
Related Pathways
Its related pathways are RET signaling and Formation of Fibrin Clot (Clotting Cascade).
Function
Thrombin cleaves the bond after Arg and Lys, converts fibrinogen into fibrin, and activates factors V, VII, VIII, XIII and protein c, a complex with thrombomodulin. Thrombin plays a role in blood homeostasis, inflammation and wound healing.
Post-translational modifications
The gamma-carboxyglutamyl residues, which bind calcium ions, result from the carboxylation of glutamyl residues by a microsomal enzyme, the vitamin K-dependent carboxylase. The modified residues are necessary for the calcium-dependent interaction with a negatively charged phospholipid surface, which is essential for the conversion of prothrombin to thrombin. N-glycosylated. N-glycan heterogeneity at Asn-121: Hex3HexNAc3 (minor), Hex4HexNAc3 (minor) and Hex5HexNAc4 (major). At Asn-143: Hex4HexNAc3 (minor) and Hex5HexNAc4 (major).
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG4
Antibody Clone
ichorcumab
Host
Human
Species Reactivity
Human
Description
Ichorcumab is a synthetic fully human IgG4 that binds with high affinity and specificity to the exosite 1 region on thrombin. Ichorcumab powerfully inhibits both venous and arterial thrombosis in preclinical models. Ichorcumab is at least as powerful an anticoagulant as approved drugs such as warfarin or the novel oral anticoagulants (NOACs).
Indication
Thromboembolism

Thromboembolism

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany